eXoZymes, Inc.(EXOZ)Earnings, Financials & Key Ratios
EXOZ•NASDAQ
Price updated Jun 19, 2026
AbouteXoZymes, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The company was founded in 2014 and is headquartered in Monrovia, California.Show more
- Revenue$0
- EBITDA-$6M-254.2%
- Net Income-$6M-187.5%
- EPS (Diluted)-0.72-188.0%
- ROE-116.8%+71.7%
EXOZ Key Insights
eXoZymes, Inc. (EXOZ) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Weak momentum: RS Rating 12 (bottom 12%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when EXOZ posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
EXOZ Price & Volume
eXoZymes, Inc. (EXOZ) stock price & volume — 10-year historical chart
Loading chart...
EXOZ Growth Metrics
eXoZymes, Inc. (EXOZ) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-62.76%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-93.65%
Return on Capital
10 Years-84.49%
5 Years-84.49%
3 Years-90.51%
Last Year-92.37%
EXOZ Peer Comparison
eXoZymes, Inc. (EXOZ) competitors in Life Science Tools and Reagents — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 GEVO | 374.85M | 1.54 | -11 | 8.49% | -19.38% | -7.19% | 0.36 | |
 LNZA | 13.19M | 6.00 | -0.27 | 12.61% | -76.05% | -12.68% | ||
 MCRB | 63.67M | 6.61 | 10.33 | -40.89% | -127.3% | 1.88 | ||
 CODX | 3.76M | 3.37 | -0.10 | -84.1% | -67.54% | -164.92% | 0.06 | |
 NUVB | 1.93B | 5.56 | -9.27 | 6.99% | -102.06% | -44.1% | 0.03 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 |
Compare EXOZ vs Peers
eXoZymes, Inc. (EXOZ) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
EXOZ Income Statement
eXoZymes, Inc. (EXOZ) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - |
Cost of Goods Sold | 59.41K | 147.75K | 0 | 267.38K | 281.93K |
COGS % of Revenue | - | - | - | - | - |
Gross Profit | -59.41K▲ 0% | -147.75K▼ 148.7% | 0▲ 100.0% | -267.38K▲ 0% | -281.93K▲ 0% |
Gross Margin % | - | - | - | - | - |
Gross Profit Growth % | - | -148.72% | 100% | - | - |
Operating Expenses | 1.23M | 1.18M | 1.8M | 5.66M | 8.72M |
OpEx % of Revenue | - | - | - | - | - |
Selling, General & Admin | 778.99K | 836.83K | 1.34M | 3.8M | 5.6M |
SG&A % of Revenue | - | - | - | - | - |
Research & Development | 454.45K | 348.08K | 527.48K | 1.87M | 3.23M |
R&D % of Revenue | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | -70.07K | 0 | -100.92K |
Operating Income | -1.29M▲ 0% | -1.33M▼ 3.1% | -1.8M▼ 34.8% | -5.93M▼ 230.3% | -9M▲ 0% |
Operating Margin % | - | - | - | - | - |
Operating Income Growth % | - | -3.08% | -34.78% | -230.25% | - |
EBITDA | -1.23M | -1.18M | -1.6M | -5.66M | -8.72M |
EBITDA Margin % | - | - | - | - | - |
EBITDA Growth % | - | 3.93% | -34.97% | -254.2% | -86.57% |
D&A (Non-Cash Add-back) | 59.41K | 147.75K | 196.94K | 267.38K | 281.93K |
EBIT | -1.21M | -1.33M | -1.8M | -5.86M | -8.44M |
Net Interest Income | 0 | 98 | 100 | 77.61K | 170.86K |
Interest Income | 0 | 98 | 100 | 77.61K | 170.86K |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 83.74K | 98 | -199.9K | 70.77K | 662.48K |
Pretax Income | -1.21M▲ 0% | -1.33M▼ 10.2% | -2M▼ 49.8% | -5.86M▼ 193.6% | -8.34M▲ 0% |
Pretax Margin % | - | - | - | - | - |
Income Tax | 0 | 63.56K | 42.27K | 0 | -2.14K |
Effective Tax Rate % | 0% | -4.77% | -2.12% | 0% | 0.03% |
Net Income | -1.21M▲ 0% | -1.4M▼ 15.5% | -2.04M▼ 46.0% | -5.86M▼ 187.5% | -8.34M▲ 0% |
Net Margin % | - | - | - | - | - |
Net Income Growth % | - | -15.47% | -46% | -187.55% | -62.76% |
Net Income (Continuing) | -1.21M | -1.4M | -2.04M | -5.86M | -8.34M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.15▲ 0% | -0.17▼ 13.3% | -0.25▼ 47.1% | -0.72▼ 188.0% | -0.99▲ 0% |
EPS Growth % | - | -13.33% | -47.06% | -188% | -93.65% |
EPS (Basic) | -0.15 | -0.17 | -0.25 | -0.72 | - |
Diluted Shares Outstanding | 8.13M | 8.13M | 8.13M | 8.13M | 8.39M |
Basic Shares Outstanding | 8.13M | 8.13M | 8.13M | 8.13M | 8.39M |
Dividend Payout Ratio | - | - | - | - | - |
EXOZ Balance Sheet
eXoZymes, Inc. (EXOZ) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|
Total Current Assets | 1.05M | 1.47M | 1.21M | 10.82M | 5.61M |
Cash & Short-Term Investments | 547.81K | 558.57K | 66.53K | 9.72M | 5.1M |
Cash Only | 547.81K | 558.57K | 66.53K | 9.72M | 5.1M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 468.35K | 809.53K | 882.32K | 737.28K | 0 |
Days Sales Outstanding | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - |
Other Current Assets | 30.19K | 101.14K | 264.76K | 363.79K | 507.36K |
Total Non-Current Assets | 1.3M | 1.22M | 2.34M | 2.21M | 2.11M |
Property, Plant & Equipment | 1.3M | 1.22M | 2.34M | 2.21M | 2.28M |
Fixed Asset Turnover | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | -274.3K |
Total Assets | 2.35M▲ 0% | 2.69M▲ 14.5% | 3.56M▲ 32.5% | 13.03M▲ 266.3% | 7.72M▲ 0% |
Asset Turnover | - | - | - | - | 0.00x |
Asset Growth % | - | 14.47% | 32.5% | 266.29% | 709.57% |
Total Current Liabilities | 400.78K | 634.36K | 2.42M | 1.33M | 1.24M |
Accounts Payable | 267.3K | 385.8K | 702.91K | 924.25K | 904.35K |
Days Payables Outstanding | 1.64K | 953.06 | - | 1.26K | 1.24K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 1M | 0 | 334.01K |
Current Ratio | 2.61x | 2.32x | 0.50x | 8.12x | 4.53x |
Quick Ratio | 2.61x | 2.32x | 0.50x | 8.12x | 4.53x |
Cash Conversion Cycle | - | - | - | - | - |
Total Non-Current Liabilities | 748.25K | 678.77K | 1.53M | 1.28M | 1.11M |
Long-Term Debt | 0 | 0 | 0 | 0 | 1M |
Capital Lease Obligations | 587.14K | 463.77K | 1.39M | 1.16M | 3.35M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 123.58K | 103.06K |
Total Liabilities | 1.15M | 1.31M | 3.94M | 2.61M | 2.34M |
Total Debt | 720.63K | 608.77K | 1.61M | 1.39M | 1M |
Net Debt | 172.82K | 50.2K | 1.55M | -8.33M | -4.1M |
Debt / Equity | 0.60x | 0.44x | - | 0.13x | 0.19x |
Debt / EBITDA | - | - | - | - | -0.12x |
Net Debt / EBITDA | - | - | - | - | 0.47x |
Interest Coverage | - | - | - | - | - |
Total Equity | 1.2M▲ 0% | 1.37M▲ 14.7% | -384.32K▼ 128.0% | 10.42M▲ 2811.5% | 5.37M▲ 0% |
Equity Growth % | - | 14.66% | -128% | 2811.49% | 4291.12% |
Book Value per Share | 0.15 | 0.17 | -0.05 | 1.28 | 0.64 |
Total Shareholders' Equity | 1.2M | 1.37M | -384.32K | 10.42M | 5.37M |
Common Stock | 12 | 6 | 6 | 8 | 8 |
Retained Earnings | -2.65M | -4.05M | -6.08M | -11.95M | -18.45M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
EXOZ Cash Flow Statement
eXoZymes, Inc. (EXOZ) cash flow — operating, investing & free cash flow history
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|
Cash from Operations | -1.59M | -1.26M | -1.18M | -8.51M | -10.24M |
Operating CF Margin % | - | - | - | - | - |
Operating CF Growth % | - | 20.77% | 6.06% | -620.29% | -1335.25% |
Net Income | -1.21M | -1.4M | -2.04M | -5.86M | -8.34M |
Depreciation & Amortization | 59.41K | 147.75K | 196.94K | 267.38K | 112.01K |
Stock-Based Compensation | 198.46K | 216.5K | 281.54K | 1.13M | 1.63M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -99K | -35.15K | 158.73K | -19.4K | 161.44K |
Working Capital Changes | -536.48K | -190.07K | 220.31K | -4.02M | -3.8M |
Change in Receivables | -317.07K | -341.18K | -72.79K | 145.04K | 145.49K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -214.43K | 118.5K | 272.89K | 221.34K | 280.35K |
Cash from Investing | -312.25K | -87.21K | -311.17K | -359.22K | -285.63K |
Capital Expenditures | -422.59K | -185.98K | -288.71K | -396.45K | -305.33K |
CapEx % of Revenue | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - |
Other Investing | 110.33K | 98.77K | -22.45K | 37.23K | 19.7K |
Cash from Financing | 2.31M | 1.36M | 1M | 18.52M | 15.39M |
Debt Issued (Net) | 0 | 0 | 0 | 3.98M | -599.22K |
Equity Issued (Net) | 1000K | 1000K | 0 | 1000K | 1000K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 1M | 11.82K | 1.44M |
Net Change in Cash | 413.45K▲ 0% | 10.76K▼ 97.4% | -492.04K▼ 4671.1% | 9.65M▲ 2061.8% | 4.86M▲ 0% |
Free Cash Flow | -2.01M▲ 0% | -1.44M▲ 28.2% | -1.47M▼ 1.8% | -8.9M▼ 505.8% | -10.54M▲ 0% |
FCF Margin % | - | - | - | - | - |
FCF Growth % | - | 28.18% | -1.84% | -505.76% | -171.87% |
FCF per Share | -0.25 | -0.18 | -0.18 | -1.10 | -1.26 |
FCF Conversion (FCF/Net Income) | 1.31x | 0.90x | 0.58x | 1.45x | 1.26x |
Interest Paid | 0 | 0 | 0 | 0 | 2.38K |
Taxes Paid | 0 | 0 | 63.56K | 0 | -42.27K |
EXOZ Key Ratios
eXoZymes, Inc. (EXOZ) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|
Return on Equity (ROE) | -108.66% | -412.54% | -116.8% | -155.17% |
Return on Invested Capital (ROIC) | -71.58% | -104.28% | -273.85% | -402.69% |
Debt / Equity | 0.44x | - | 0.13x | 0.19x |
FCF Conversion | 0.90x | 0.58x | 1.45x | 1.26x |
Related:EXOZ Dividend History·EXOZ Revenue History·EXOZ Price History·EXOZ P/E History·EXOZ Financial Ratios·EXOZ Institutional Holders
EXOZ Frequently Asked Questions
eXoZymes, Inc. (EXOZ) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
eXoZymes, Inc. (EXOZ) grew revenue by 0.0% over the past year. Growth has been modest.
eXoZymes, Inc. (EXOZ) reported a net loss of $8.3M for fiscal year 2024.
Dividend & Returns
eXoZymes, Inc. (EXOZ) has a return on equity (ROE) of -116.8%. Negative ROE indicates the company is unprofitable.
eXoZymes, Inc. (EXOZ) had negative free cash flow of $10.5M in fiscal year 2024, likely due to heavy capital investments.